Frequency Distribution of CYP2C9 and VKORC1 Mutations among Bulgarian Patients and their Importance for Anticoagulant Therapy

被引:0
|
作者
Velizarova, Milena [1 ,2 ]
Abedinov, Philip [3 ]
Svinarov, Dobrin [1 ,2 ]
Nikolov, Valentin [4 ]
Hristova, Julieta [1 ,2 ]
机构
[1] Med Univ Sofia, Fac Med, Dept Clin Lab, Sofia, Bulgaria
[2] Alexander Univ Hosp, Sofia, Bulgaria
[3] St Ekaterina Univ Hosp, Sofia, Bulgaria
[4] SGP Bio Dynam Ltd, Sofia, Bulgaria
关键词
CYP2C9; oral anticoagulants; pharmacogenetics; VKORC1; GENETIC POLYMORPHISMS; PRESCRIBING ERRORS; WARFARIN; PREVALENCE; REQUIREMENT; GENOTYPE;
D O I
10.7754/Clin.Lab.2022.220213
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Genetic polymorphisms of CYP2C9 and VKORC1 play a major role in pharmacokinetics and pharmacodynamics of coumarin anticoagulants. The purpose of our study was to assess the relative frequency of the above mutations in Bulgarian population in order to predict bleeding tendencies and precisely manage the anticoagulant therapy during the postoperative period after cardiac surgery with extracorporeal circulation. Methods: Genomic DNA samples from 200 Bulgarian patients subjected to cardiac surgery with extracorporeal circulation were analyzed for VKORC1 1639G>A and CYP2C9*2&*3 polymorphisms by real-time polymerase chain reaction (PCR), then allele frequencies of various genotypes were calculated by Hardy-Weinberg Equilibrium. Results: Median patients' age was 63.9 +/- 10.8 years; 66.5% were male. Median BMI was 28.6 +/- 5.4 kg/m 2 . Genotype distribution for CYP2C9 was *1/*1 - 51%, *1/*2 - 21%, *1/*3 - 13.5%, *2/*3 - 4%, *3/*3 - 2%, and *2/*2 1.5%. The calculated frequency of CYP2C9*1 allele was 74.25%, CYP2C9*2 allele was 13%, and CYP2C9*3 allele was 12.75%, and all allelic frequencies were in Hardy-Weinberg equilibrium (p-value = 0.358). The major VKORC1 genotype was G/A - 47%, followed by G/G - 35.5% and A/A - 17.5%). Based on Hardy-Weinberg Equilibrium, there was no significant difference between observed and expected frequencies (X - -3.779), presumably as a result of the homogeneity in the population. Conclusions: Analysis of the data obtained in the course of the study suggested that identification of homozygous carriers of VKORC1-1639 G>A (rs9923231) in Bulgarians may be useful in developing recommendations for personalized therapy. On the contrary, homozygous carriers of CYP2C9*2 or *3, included only 4.5% of the studied patients, thus indicating that this group would benefit less from dosing algorithms. Our results demonstrated good agreement with the results obtained in other studies conducted in the Caucasian population.
引用
收藏
页码:2527 / 2532
页数:6
相关论文
共 50 条
  • [31] Investigation of allele and genotype frequencies of CYP2C9, CYP2C19 and VKORC1 in Iran
    Azarpira, Negar
    Namazi, Soha
    Hendijani, Fatemeh
    Banan, Maryam
    Darai, Masumeh
    PHARMACOLOGICAL REPORTS, 2010, 62 (04) : 740 - 746
  • [32] Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 -: Rationale and perspectives
    Yin, Tong
    Miyata, Toshiyuki
    THROMBOSIS RESEARCH, 2007, 120 (01) : 1 - 10
  • [33] Mutations in CYP2C9 and/or VKORC1 haplotype are associated with higher bleeding complications in patients with Budd-Chiari syndrome on warfarin
    Shukla, Akash
    Jain, Abhinav
    Kahalekar, Vinit
    Bendkhale, Sheetal
    Gogtay, Nithya
    Thatte, Urmila
    Bhatia, Shobna
    HEPATOLOGY INTERNATIONAL, 2019, 13 (02) : 214 - 221
  • [34] Platform evaluation for rapid genotyping of CYP2C9 and VKORC1 alleles
    Joshi, Victoria A.
    Duffy, Elizabeth
    Funke, Birgit H.
    Farwell, Lisa M.
    Mancini-Dinardo, Debora
    Kucherlapati, Raju
    PERSONALIZED MEDICINE, 2009, 6 (04) : 449 - 457
  • [35] Genotype of the VKORC1 and CYP2C9 genes in the individual response to warfarin
    Esperon, Patricia
    Raggio, Victor
    Goyeneche, Lucia
    Lorenzo, Mariana
    Taub, Irene
    Stoll, Mario
    REVISTA MEDICA DEL URUGUAY, 2008, 24 (04): : 266 - 276
  • [36] Impact of CYP2C9 and VKORC1 Polymorphisms on Warfarin Sensitivity and Responsiveness in Jordanian Cardiovascular Patients during the Initiation Therapy
    AL-Eitan, Laith N.
    Almasri, Ayah Y.
    Khasawneh, Rame H.
    GENES, 2018, 9 (12):
  • [37] Frequency distribution of polymorphisms of CYP2C19, CYP2C9, VKORC1 and SLCO1B1 genes in the Yakut population
    Vasilyev, Filipp Filippovich
    Danilova, Diana Aleksandrovna
    Kaimonov, Vladimir Sergeevich
    Chertovskih, Yana Valerievna
    Maksimova, Nadezda Romanovna
    RESEARCH IN PHARMACEUTICAL SCIENCES, 2016, 11 (03) : 259 - 264
  • [38] Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients
    Mushiroda, T
    Ohnishi, Y
    Saito, S
    Takahashi, A
    Kikuchi, Y
    Saito, S
    Shimomura, H
    Wanibuchi, Y
    Suzuki, T
    Kamatani, N
    Nakamura, Y
    JOURNAL OF HUMAN GENETICS, 2006, 51 (03) : 249 - 253
  • [39] Influence of CYP2C9 and VKORC1 Polymorphisms on Warfarin and Acenocoumarol in a Sample of Lebanese People
    Esmerian, Maria O.
    Mitri, Zahi
    Habbal, Mohammad-Zuheir
    Geryess, Eddy
    Zaatari, Ghazi
    Alam, Samir
    Skouri, Hadi N.
    Mahfouz, Rami A.
    Taher, Ali
    Zgheib, Nathalie K.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 51 (10) : 1418 - 1428
  • [40] The impact of the CYP2C9 and VKORC1 polymorphisms on acenocoumarol dose requirements in a Romanian population
    Buzoianu, Anca Dana
    Militaru, Florentina Claudia
    Vesa, Stefan Cristian
    Trifa, Adrian Pavel
    Crisan, Sorin
    BLOOD CELLS MOLECULES AND DISEASES, 2013, 50 (03) : 166 - 170